S&P 500: 681.75 +0.1% NASDAQ 100: 601.92 +0.2% Dow Jones: 495.28 +0.1%

Louis Moore Bacon’s RVMD Holdings & Trades

First Buy
Q4 2023
Duration Held
8 Quarters
Largest Add
Q4 2023
+55,600 Shares
Current Position
55,600 Shares
$2.6 M Value

Louis Moore Bacon's RVMD Position Overview

Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 55,600 shares of Revolution Medicines, Inc. (RVMD) worth $2.6 M, representing 0.04% of the portfolio. First purchased in 2023-Q4, this short-term holding has been held for 8 quarters.

Based on 13F filings, Louis Moore Bacon has maintained this position in RVMD for several quarters, showing initial confidence in the investment.

Analysis based on 13F filings available since 2013 Q2

Louis Moore Bacon's Revolution Medicines (RVMD) Holding Value Over Time

Track share changes against reported price movement

Quarterly Revolution Medicines (RVMD) Trades by Louis Moore Bacon

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2023 +55,600 New Buy 55,600 $28.68

Louis Moore Bacon's Revolution Medicines Investment FAQs

Louis Moore Bacon first purchased Revolution Medicines, Inc. (RVMD) in Q4 2023, acquiring 55,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Louis Moore Bacon has held Revolution Medicines, Inc. (RVMD) for 8 quarters since Q4 2023.

Louis Moore Bacon's largest addition to Revolution Medicines, Inc. (RVMD) was in Q4 2023, adding 55,600 shares worth $1.59 M.

According to the latest 13F filing for Q3 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 55,600 shares of Revolution Medicines, Inc. (RVMD), valued at approximately $2.6 M.

As of the Q3 2025 filing, Revolution Medicines, Inc. (RVMD) represents approximately 0.04% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.

Louis Moore Bacon's peak holding in Revolution Medicines, Inc. (RVMD) was 55,600 shares, as reported at the end of Q4 2023.